UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007926
Receipt number R000008681
Scientific Title Study of Sitagliptin Treatment for Glycemic Control and Prevention of GAD-Ab Positive Non-insulin Dependent Diabetes Mellitus in Osaka
Date of disclosure of the study information 2012/05/11
Last modified on 2012/05/06 18:57:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of Sitagliptin Treatment for Glycemic Control and Prevention of GAD-Ab Positive Non-insulin Dependent Diabetes Mellitus in Osaka

Acronym

STGP-OSAKA

Scientific Title

Study of Sitagliptin Treatment for Glycemic Control and Prevention of GAD-Ab Positive Non-insulin Dependent Diabetes Mellitus in Osaka

Scientific Title:Acronym

STGP-OSAKA

Region

Japan


Condition

Condition

GAD-Ab positive non-insulin dependent diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of sitagliptin versus insulin on Glycemic Control and Prevention of GAD-Ab Positive Non-insulin Dependent Diabetes Mellitus

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of patients indicated an insulin-dependent state during 3 years.
Rate of patients indicated an insulin-dependent state.

Key secondary outcomes

Change of HbA1c value.
Change of Fasted plasma glucose, Fasted serum CPR value.
Glucose level, glucagon level and C-peptide values during the liquid mixed-meal test.
Average amount of insulin per a day.
Rate of hypoglycemia. etc


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation

YES

Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Sitagliptin group
Sitagliptine begin with 50 mg once daily (max dose 100mg).
Addition of metformin and/or alpha-GI are possible after increasing the dose of sitagliptine to 100mg.

Interventions/Control_2

Control group
Subcutaneous insulin administration to the control group patients. The dosage is adjusted.
If necessary, addition of metformin and/or alpha-GI are possible.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Patients who met the criteria for diabetes mellitus.
1. Duration of diabetes should be within 5 yr from onset (or diagnosis).
2. GADAb positive: 1.5U/ml or higher
3. fasting serum C-peptide: 0.5ng/ml or higher
4. HbA1c(NGSP): <8.4%
FPG: <160mg/dl

Key exclusion criteria

1. Injection of insulin within 3 month before entry point
2. Pregnant or planning to be pregnant
3. Diabetic nephropathy: Class 3 or higher
4. Diabetic retinopathy:
Preproliferative or higher
5. NYHA 3-4
6. History in use of DPP-4 inhibitor or GLP-1 analogue.
7. Physician's judgment.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mitsuyoshi Namba

Organization

Hyogo College of Medicine

Division name

Division of Diabetes and Metabolism, Department of Internal Medicine

Zip code


Address

1-1, Mukogawa-chi, Nishinomiya, Hyogo, 663-8501 Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Jun-ichiro Miyagawa

Organization

Hyogo college of medicine

Division name

Division of Diabetes and Metabolism, Department of Internal Medicine

Zip code


Address

1-1, Mukogawa-chi, Nishinomiya, Hyogo, 663-8501 Japan

TEL

0798-45-6111

Homepage URL


Email



Sponsor or person

Institute

STGP-OSAKA study group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 02 Month 03 Day

Date of IRB


Anticipated trial start date

2012 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 05 Month 10 Day

Last modified on

2012 Year 05 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008681


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name